Antitumor activity of suberoylanilide hydroxamic acid against human oral squamous cell carcinoma cell lines in vitro and in vivo

Oral Oncology

Volumn 45, Issue 9, 2009, Pages 766-770

  Nagumo, Tatsuhito ^a   Takaoka, Sayaka ^a   Yoshiba, Sayaka ^a   Ohashi, Masaru ^a   Shirota, Tatsuo ^a   Hatori, Masashi ^a   Isobe, Tomohide ^a   Tachikawa, Tetsuhiko ^a   Shintani, Satoru ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Cell cycle; Oral cancer; Oral squamous cell carcinoma; p21; p53; Suberoylanilide hydroxamic acid (SAHA)

Indexed keywords

PROTEIN P21; PROTEIN P53; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR MECHANICS; MOUSE; MOUTH CARCINOMA; NONHUMAN; NUDE MOUSE; ORAL SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; G1 PHASE; HUMANS; HYDROXAMIC ACIDS; MICE; MICE, NUDE; MOUTH NEOPLASMS; S PHASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 68949197601     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2008.11.009     Document Type: Article

References (25)

1. Clayman G.L., Ebihara S., Terada M., Mukai K., and Goepfert H. Report of the tenth international symposium of the foundation for promotion of cancer research: basic and clinical research in head and neck cancer. Jap J Clin Oncol 27 (1997) 361-368
2. Luger K., Mader A.W., Richmond R.K., Sargent D.F., and Richmond T.J. Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature 389 (1997) 251-254
3. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1 (2001) 194-202
4. Norton V.G., Imai B.S., Yau P., and Bradbury E.M. Histone acetylation reduces nucleosome core particle linking number change. Cell 57 (1989) 449-457
5. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1 (2002) 287-299
6. McLaughlin F., and La Thangue N.B. Histone deacetylase inhibitors open new doors in cancer therapy. Biochem Pharmacol 68 (2004) 1139-1144
7. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6 (2006) 38-51
8. Jung M. Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem 8 (2001) 1505-1511
9. Wade P.A. Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet 10 (2001) 693-698
10. Glaser K.B., Staver M.J., Waring J.F., Stender J., Ulrich R.G., and Davidsen S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2 (2003) 151-163
11. Villar-Garea A., and Esteller M. Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer 112 (2004) 171-178
12. Richon V.M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R.A., et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95 (1998) 3003-3007
13. Sakajiri S., Kumagai T., Kawamata N., Saitoh T., Said J.W., and Koeffler H.P. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 33 (2005) 53-61
14. Butler L.M., Agus D.B., Scher H.I., Higgins B., Rose A., Cordon-Cardo C., et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60 (2000) 5165-5170
15. Takai N., Kawamata N., Gui D., Said J.W., Miyakawa I., and Koeffler H.P. Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 101 (2004) 2760-2770
16. Takai N., Desmond J.C., Kumagai T., Gui D., Said J.W., Whittaker S., et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 10 (2004) 1141-1149
17. Richardson P., Mitsiades C., Colson K., Reilly E., McBride L., Chiao J., et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 49 (2008) 502-507
18. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W.G., et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111 (2008) 1060-1066
19. Sakajiri S., Kumagai T., Kawamata N., Saitoh T., Said J.W., and Koeffler H.P. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 33 (2005) 53-61
20. Luong Q.T., O'Kelly J., Braunstein G.D., Hershman J.M., and Koeffler H.P. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res 12 (2006) 5570-5577
21. Richon V.M., Sandhoff T.W., Rifkind R.A., and Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97 (2000) 10014-10019
22. Taylor W.R., and Stark G.R. Regulation of the G2/M transition by p53. Oncogene 20 (2001) 1803-1815
23. Gartel A.L., and Tyner A.L. Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res 246 2 (1999) 280-289
24. Nakano K., Mizuno T., Sowa Y., Orita T., Yoshino T., Okuyama Y., et al. Butyrate activates theWAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem 272 35 (1997) 22199-22206
25. Zhao Y., Lu S., Wu L., Chai G., Wang H., Chen Y., et al. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol 26 7 (2006) 2782-2790